within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B05X_IVSolutionAdditives.B05XB03_Lysine;

model Lysine
  extends Pharmacolibrary.Drugs.ATC.B.B05XB03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>B05XB03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lysine is an essential amino acid used primarily as a nutritional supplement and for the treatment of lysine deficiency states. Intravenously, lysine has been explored as a component of amino acid solutions for parenteral nutrition and as a renal radioprotector during peptide receptor radionuclide therapy (PRRT). Lysine itself is not typically used as a standalone drug but is included within certain medical or metabolic contexts. Lysine is approved for use as a nutritional supplement, but intravenous formulations for therapeutic or diagnostic use (e.g., renal protection) are typically off-label or investigational.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for intravenous lysine in healthy adults based on available literature for amino acid infusion. Direct published PK models specifically for lysine with ATC B05XB03 are not available; these are general estimates extrapolated from parenteral amino acid/supplement studies.</p><h4>References</h4><ol><li><p>Zhao, LS, et al., &amp; Bi, KS (2012). Comparative pharmacokinetics of cefuroxime lysine after single intravenous, intraperitoneal, and intramuscular administration to rats. <i>Acta pharmacologica Sinica</i> 33(11) 1348–1352. DOI:<a href=\"https://doi.org/10.1038/aps.2012.99\">10.1038/aps.2012.99</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23064723/\">https://pubmed.ncbi.nlm.nih.gov/23064723</a></p></li><li><p>Boyd, BJ, et al., &amp; Porter, CJ (2006). Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats. <i>Molecular pharmaceutics</i> 3(5) 614–627. DOI:<a href=\"https://doi.org/10.1021/mp060032e\">10.1021/mp060032e</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17009860/\">https://pubmed.ncbi.nlm.nih.gov/17009860</a></p></li><li><p>Groll, AH, et al., &amp; Walsh, TJ (2005). Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. <i>The Journal of antimicrobial chemotherapy</i> 56(5) 899–907. DOI:<a href=\"https://doi.org/10.1093/jac/dki287\">10.1093/jac/dki287</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16172108/\">https://pubmed.ncbi.nlm.nih.gov/16172108</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Lysine;
